IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process
IntelGenx Begins Restructuring Proceedings Under CCAA to Implement Review of Strategic Alternatives
IntelGenx (IGX.TO) over the holiday weekend said that it secured an initial order from the Quebec Superior Court (Commercial Division) granting protection to the company and its subsidiaries under the
IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of Its Strategic Alternatives
Canadian Investment Regulatory Organization Trading Halt - IGX
Intelgenx Technologies Corp. | 10-Q: Quarterly report
IntelGenx Announces Voting Results on Election of Directors
IntelGenx Announces First Parkinson's Disease Patients Dosed With Montelukast VersaFilm in Phase 2 'MONTPARK' Clinical Trial
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
IntelGenx Technologies Corp. (PNK:IGXT) Q4 2023 Earnings Call Transcript
Earnings Call Summary | Intelgenx Technologies Corp.(IGXT.US) Q4 2023 Earnings Conference
The following is a summary of the IntelGenx Technologies Corp. (IGXT) Q4 2023 Earnings Call Transcript:Financial Performance:IntelGenx reported Q4 total revenue of $426,000, a 146% increase compared t
IntelGenx GAAP EPS of -$0.01, Revenue of $0.43M
IntelGenx Technologies 4Q Rev $426,000 >IGX.T
IntelGenx Technologies 4Q Rev $426,000 >IGX.T
IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results
SAINT LAURENT, Quebec, March 21, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and
IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 - Conference Call to Follow
IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow
SAINT LAURENT, Quebec, March 14, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) ("IntelGenx"), a leader in pharmaceutical films, today announced that it will release its fourth quarter and
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With Atai Life Sciences
IntelGenx Brief: Launching Regulation A Offering of Up to 2 Million Shares In Series A Convertible Cumulative Preferred Stock, Par Value $0.00001 Per Share, at an Offering Price of $10.00 Each, For a Max Offering Amount of $20 Million
07:52 AM EST, 02/20/2024 (MT Newswires) -- IntelGenx Brief: Launching Regulation A Offering of Up to 2 Million shares In Series A Convertible Cumulative Preferred Stock, Par Value $0.00001 Per Share,
IntelGenx Launches Preferred Share Regulation A Offering
Studies Validate Advantages of Administering Drugs to Pets via IntelGenx's VetaFilm Platform
IntelGenx Announces New Animal Health Partnership; Enters Into Development and License Agreements for VetaFilm
SAINT LAURENT, Quebec, Dec. 18, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has entered into development and license agreements
No Data